List of Excipients in Branded Drug FLUORESCITE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Inc	FLUORESCITE	fluorescein sodium	0065-0092	HYDROCHLORIC ACID
Alcon Inc	FLUORESCITE	fluorescein sodium	0065-0092	SODIUM HYDROXIDE
Alcon Inc	FLUORESCITE	fluorescein sodium	0065-0092	WATER

Fluorescite Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Fluorescite is an FDA-approved, preservative-free intravenous fluorescein sodium injection used for diagnostic fluorescein angiography. Its formulation is deliberately simple: fluorescein sodium in Water for Injection, with sodium hydroxide and/or hydrochloric acid used for pH adjustment. The primary commercial opportunity is not a novel excipient platform. It is a reliable, ready-to-use, sterile presentation supported by container compatibility, light protection, manufacturing consistency, and supply assurance. The product has limited active-ingredient patent protection and is exposed to conventional generic competition.

What is Fluorescite and how is it formulated?

Fluorescite is a 10% fluorescein injection containing 100 mg/mL of fluorescein sodium. It is administered intravenously before retinal or ophthalmic imaging procedures. The product is supplied as a sterile single-dose injectable presentation and is not intended for intrathecal, intramuscular, or subcutaneous administration (U.S. Food and Drug Administration [FDA], 2019).

Attribute	Fluorescite profile
Active ingredient	Fluorescein sodium
Strength	100 mg/mL, equivalent to a 10% solution
Dosage form	Sterile intravenous injection
Primary use	Diagnostic fluorescein angiography
Route	Intravenous
Preservative	No preservative identified in the FDA labeling
Core solvent	Water for Injection
pH adjustment	Sodium hydroxide and/or hydrochloric acid
Typical commercial container	Single-dose vial presentation
Product category	Small-molecule diagnostic agent
FDA pathway	New drug application approval; generic competition would generally use an ANDA pathway if the reference standard is appropriate

The label identifies sodium hydroxide and hydrochloric acid as formulation components used for pH adjustment. It does not describe a functional excipient system involving surfactants, antioxidants, antimicrobial preservatives, complexing agents, or viscosity modifiers (FDA, 2019).

What excipients are used in Fluorescite?

The commercial formulation has three practical excipient functions:

1. Water for Injection provides the aqueous vehicle.
2. Sodium hydroxide adjusts formulation pH upward.
3. Hydrochloric acid adjusts formulation pH downward.

This composition has several development advantages. It minimizes the number of injectable materials, limits excipient-related toxicology work, reduces supply-chain complexity, and supports a clean-label positioning for ophthalmic diagnostic use.

The simplicity also creates constraints. Fluorescein sodium is highly colored, and its chemical behavior can vary with pH, ionic strength, temperature, light exposure, oxygen exposure, and container-contact surfaces. A formulation developer cannot assume that adding a common stabilizer or buffer will improve the product. Any new excipient would require assessment of:

• Intravenous tolerability
• Local venous irritation
• Compatibility with fluorescein sodium
• Impact on fluorescence intensity
• Impact on angiographic image quality
• Visible and subvisible particles
• Extractables and leachables
• Sterilization effects
• Container closure integrity
• Long-term and in-use stability

For this product class, a minimal formulation is commercially attractive because additional excipients can create more regulatory and clinical risk than value.

How strong is the Fluorescite excipient strategy?

The current strategy is strong for regulatory simplicity but weak as a standalone composition-of-matter barrier.

Regulatory strengths

A low-excipient formulation can reduce:

• Excipient qualification requirements
• Compatibility investigations
• Analytical method development
• Risk of hypersensitivity attributable to formulation additives
• Batch-to-batch variability
• Manufacturing deviations
• Labeling complexity

This strategy is particularly suitable for a diagnostic injectable used in controlled clinical settings. The product does not need sustained release, tissue targeting, viscosity control, or prolonged residence time.

Technical weaknesses

The formulation remains exposed to several technical risks:

• Light-related degradation or potency drift
• pH-dependent changes in fluorescence performance
• Adsorption or interaction with elastomeric components
• Particulate formation
• Container discoloration or visual inspection challenges
• Differences in fluorescence response between batches
• Potential compatibility issues with infusion lines and syringes

A meaningful commercial advantage could therefore come from process and packaging control rather than a new excipient.

What formulation patents could protect Fluorescite or a competing product?

The fluorescein sodium active ingredient is an old chemical entity and is not expected to have meaningful remaining composition-of-matter exclusivity. The commercial protection available to a new entrant would more likely involve:

• A specific concentration or pH range
• A stability-enhancing formulation
• A light-protective container system
• A low-particulate injectable formulation
• A prefilled syringe or ready-to-administer device
• A compatible vial stopper and seal combination
• A manufacturing process that improves assay or impurity control
• A method for reducing injection-site reactions
• A specific method of use involving imaging protocols or patient populations

A patent directed only to the use of Water for Injection, sodium hydroxide, and hydrochloric acid would likely face significant validity and obviousness challenges unless it includes an unexpected stability, safety, or performance result.

The strongest formulation patent opportunity would combine a narrowly defined composition with measurable technical results. Examples include improved stability after prolonged storage, reduced impurity formation, preserved fluorescence intensity, or improved compatibility with a specific container closure.

What is the Orange Book status of Fluorescite?

Fluorescite is an FDA-approved small-molecule diagnostic product. It is not a biologic, so biosimilar regulation under the 351(k) pathway is not relevant. A competing product would generally pursue an abbreviated new drug application if it can demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable regulatory requirements for an injectable diagnostic product.

The commercial importance of Orange Book listings is limited if no enforceable listed patents remain associated with the reference product. The relevant review points are:

Orange Book issue	Commercial implication
Listed patents	Determine whether an ANDA applicant must certify under Paragraph IV
Pediatric exclusivity	Could delay approval of an ANDA if applicable
Regulatory exclusivity	Fluorescein sodium is an established active ingredient, making new chemical entity exclusivity unlikely
Method-of-use patents	May affect labeling strategy if listed and enforceable
Reference-listed drug status	Determines the reference product for generic development
Patent delisting or expiry	Reduces litigation risk and accelerates generic entry

An applicant challenging a listed patent would use a Paragraph IV certification. If no relevant patent is listed, the principal barriers become formulation equivalence, manufacturing quality, supply reliability, and commercial contracting rather than patent litigation (FDA, 2024a, 2024b).

When does Fluorescite lose exclusivity?

Fluorescein sodium has been used in medicine for decades. The active ingredient does not have meaningful remaining NCE exclusivity. Any current market protection would more likely arise from product-specific regulatory exclusivity, listed patents, manufacturing capability, or commercial positioning.

The relevant exclusivity timeline is therefore:

Period	Expected protection
Historical development period	Active ingredient and basic diagnostic use were established long ago
Fluorescite approval	Product-specific FDA approval created a regulated reference product
Post-approval period	Any applicable regulatory exclusivity depended on the approval basis and FDA designation
Current commercial period	Generic or alternative-product entry is principally a pharmaceutical-equivalence and execution question
Future	Device, container, process, or differentiated formulation claims could create limited secondary protection

The exact expiry of any product-specific regulatory exclusivity or listed patent must be confirmed in the current Orange Book and FDA exclusivity records before a launch decision. The underlying active ingredient itself does not provide a durable exclusivity position.

Are Paragraph IV challenges or generic launches likely?

Generic entry is commercially plausible because the product is a conventional aqueous injectable with an established active ingredient. The key development requirements would include:

• Quantitative and qualitative formulation comparison
• Strength and concentration matching
• Sterility assurance
• Endotoxin control
• Particulate control
• Container closure compatibility
• Stability under labeled storage conditions
• Demonstration of equivalent clinical diagnostic performance where required
• Manufacturing at a cost that supports hospital, ambulatory surgery, and ophthalmology purchasing channels

A generic sponsor could pursue one of three launch models:

Standard vial generic

This is the lowest-complexity approach. It would compete primarily on price, availability, contract terms, and backorder performance.

Ready-to-use prefilled syringe

A prefilled syringe could reduce preparation steps and medication-use errors. It may command a premium if it improves workflow in ophthalmology and radiology settings. The device would create new regulatory and patent issues involving syringe materials, dose accuracy, siliconization, closure integrity, and extractables.

Differentiated low-volume or lower-dose presentation

A lower-volume presentation could reduce waste and improve handling. The development case would depend on whether the clinical dose can be delivered without compromising angiographic image quality or creating dosing confusion.

What commercial opportunities exist for excipient and packaging innovation?

The strongest opportunities are adjacent to the formulation rather than changes to the liquid composition.

1. Light-protective packaging

A vial, overwrap, carton, or secondary package designed to limit light exposure could improve stability and reduce handling restrictions. Patent claims could focus on the interaction between the formulation and packaging system, provided the technical data show a measurable benefit.

2. Low-sorption container systems

Selecting a glass type, elastomer, coating, or syringe material that limits adsorption and extractables could support a differentiated product. This is relevant because colored injectable solutions can complicate visual inspection and may interact with container surfaces.

3. Ready-to-administer formats

A prefilled syringe or small-volume vial could reduce preparation time. Commercial value would be highest in high-throughput ophthalmology centers and imaging departments where staff time and medication preparation are material operating costs.

4. Improved particulate control

A manufacturer could differentiate through tighter particulate specifications, improved filtration, and container closure controls. These claims are more defensible as manufacturing and quality advantages than as broad excipient claims.

5. Supply-chain resilience

Fluorescein sodium products can be vulnerable to shortages if a limited number of manufacturers control sterile filling, validated raw materials, or specialized packaging. A supplier with dual-source excipient procurement, redundant sterile manufacturing, and dependable vial capacity could capture institutional contracts even without patent protection.

6. Compounding and kit integration

A diagnostic kit could combine the injection with imaging workflow materials, labeling, dosing aids, or procedure-specific packaging. The commercial value would come from procurement simplification and operational efficiency. The kit would need to preserve the drug product's approved use and avoid creating new medication errors.

How does Fluorescite compare with alternative imaging agents?

Fluorescite competes with both other dyes and non-dye imaging technologies.

Technology	Primary use	Competitive relationship
Fluorescein sodium	Retinal and choroidal vascular imaging	Direct reference product and generic target
Indocyanine green	Deeper choroidal and vascular imaging	Clinical substitute in selected cases
Optical coherence tomography	Structural retinal imaging	Partial procedural substitute
OCT angiography	Noninvasive vascular imaging	Reduces reliance on injectable dyes in selected patients
Fundus photography	Surface retinal documentation	Complementary rather than full substitute

Fluorescein angiography remains relevant where dynamic leakage, perfusion, and vascular patterns are required. OCT angiography may reduce injection use for some follow-up procedures, but it does not fully replace dye-based angiography across all indications.

What patent litigation and settlement risks affect Fluorescite?

Patent litigation risk appears lower than for a recently approved therapeutic drug because fluorescein sodium is an old active ingredient and the principal formulation is simple. Potential disputes could still arise around:

• A specific formulation range
• A prefilled syringe
• A light-protective package
• A container closure system
• A diagnostic method of use
• Trade dress or labeling
• Manufacturing know-how
• Regulatory exclusivity certifications

A Paragraph IV challenge would be most likely if an Orange Book-listed patent covered a commercially important method or formulation. If the product has no blocking listed patents, litigation would be less likely to delay entry. Settlement agreements could still occur to establish a launch date, but the bargaining leverage of a reference sponsor would be limited where the active ingredient and formulation are readily reproducible.

What revenue exposure and market opportunities exist?

Public company disclosures generally do not isolate Fluorescite revenue from broader ophthalmic pharmaceutical sales. Revenue exposure is therefore best assessed through procedure volume, product availability, and pricing rather than a publicly reported brand-specific figure.

The commercial opportunity is concentrated in:

• Ophthalmology clinics
• Retinal specialty practices
• Hospital imaging departments
• Ambulatory surgery centers
• Academic medical centers
• Distributors supplying diagnostic injectables

A branded product can preserve share through dependable supply, consistent vial quality, customer service, and institutional contracts. A generic entrant can compete through lower acquisition cost. A premium entrant needs to demonstrate operational value through a prefilled format, reduced waste, improved stability, or easier administration.

What manufacturing and intellectual-property barriers matter most?

The highest practical barriers are manufacturing-related:

1. Sterile injectable production at commercial scale.
2. Consistent fluorescein sodium raw-material quality.
3. Control of pH and degradation impurities.
4. Container closure integrity.
5. Reliable visual inspection of a strongly colored solution.
6. Low particulate and endotoxin levels.
7. Stability data supporting the proposed shelf life.
8. Commercial access to ophthalmology and hospital distribution channels.

These barriers are meaningful but manageable for established injectable manufacturers. They are weaker than the barriers associated with complex biologics, sterile lyophilized products, or advanced delivery systems.

Key Takeaways

• Fluorescite is a 10% intravenous fluorescein sodium injection used for diagnostic angiography.
• Its excipient system is minimal: Water for Injection, sodium hydroxide, and hydrochloric acid for pH adjustment.
• The core formulation is unlikely to provide strong patent protection by itself.
• The most credible innovation areas are packaging, container compatibility, prefilled delivery, light protection, particulate control, and manufacturing consistency.
• Fluorescite is a small-molecule product, so biosimilar risk does not apply.
• Generic entry is technically feasible and would likely focus on pharmaceutical equivalence, sterile manufacturing, supply reliability, and price.
• Paragraph IV litigation risk depends on current Orange Book listings rather than the age of fluorescein sodium.
• Commercial differentiation is more likely to come from workflow efficiency and supply assurance than from a new excipient.
• OCT angiography and indocyanine green create competitive pressure, but neither fully replaces fluorescein angiography across all diagnostic uses.
• The most defensible investment thesis is a reliable, ready-to-use sterile product with differentiated packaging and institutional distribution.

Frequently Asked Questions

Can a new buffer create patent protection for a Fluorescite generic?

Possibly, but a buffer alone would rarely create strong protection. The applicant would need evidence that the buffer produces an unexpected benefit, such as materially improved stability, fluorescence retention, reduced impurities, or improved tolerability.

Is fluorescein sodium suitable for a preservative-containing multidose vial?

A multidose presentation would require a separate assessment of antimicrobial preservation, repeated-entry contamination risk, intravenous safety, and container compatibility. A preservative-free single-dose format is more consistent with the current product strategy.

Could a prefilled Fluorescite syringe receive premium pricing?

Yes, if it reduces preparation time, waste, dosing errors, or staff workload. The premium would depend on device validation, reimbursement conditions, purchasing contracts, and demonstrated workflow savings.

Does Fluorescite face biosimilar competition?

No. Fluorescite contains a chemically synthesized small molecule. A competing product would be evaluated through the generic drug framework or, for a differentiated product, a suitable new drug application pathway rather than the biosimilar pathway.

What is the most valuable secondary patent strategy for a Fluorescite competitor?

The strongest secondary strategy would likely combine a defined formulation or container system with data showing improved stability, fluorescence performance, particulate control, or administration efficiency.

References

Food and Drug Administration. (2019). Fluorescite (fluorescein injection USP) prescribing information. U.S. Department of Health and Human Services.

Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services.

Food and Drug Administration. (2024b). Electronic Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

Food and Drug Administration. (2024c). Abbreviated new drug application process. U.S. Department of Health and Human Services.